Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
Other Sizes |
|
Purity: ≥98%
Hydroxyzine is a potent histamine H1-receptor antagonist which inhibits the binding of [3H]pyrilamine/[3H]desloratadine to human histamine H1 receptor with IC50 of 10 nM/19 nM. In pretreated bladder slices, hydroxyzine reduces serotonin release induced by carbachol (10 μM) by 34% at 10 μM, 25% at 1 μM, and 17% at 0.1 μM for a duration of 60 minutes. In Lewis rats with allergic encephalomyelitis (EAE), hydroxyzine (0.1 mM) treatment reduces mast cell degranulation by 70% and the course and severity of EAE by 50%. The primary metabolite of Hydroxyzine, cetirizine, does not make one drowsy.
Targets |
H1 Receptor
|
---|---|
ln Vitro |
Hydroxyzine dihydrochloride, when applied to pretreated bladder slices for 60 minutes, reduces serotonin release induced by carbachol (10 μM) by 34% at 10 μM, 25% at 1 μM, and 17% at 0.1 μM[1].
|
ln Vivo |
Hydroxyzine dihydrochloride (12.5 mg/kg, 25 mg/kg, and 50 mg/kg intraperitoneally) only significantly increases the effect of morphine on the vocalization after-discharge, which in rats is thought to be the affective component of pain. It has minimal direct analgesic activity. In the tail-flick test, hydroxyzine dihydrochloride (50 mg/kg i.p.) amplifies morphine, whereas hydroxyzine (12.5 mg/kg i.p.) reduces morphine antinociception in rats[3].
|
References |
Molecular Formula |
C21H27CLN2O2
|
---|---|
Molecular Weight |
374.91
|
Exact Mass |
374.18
|
Elemental Analysis |
C, 67.28; H, 7.26; Cl, 9.46; N, 7.47; O, 8.53
|
CAS # |
68-88-2
|
Related CAS # |
Hydroxyzine dihydrochloride; 2192-20-3; Hydroxyzine-d4 dihydrochloride; 1219805-91-0; Hydroxyzine-d8; 1189480-47-4; Hydroxyzine pamoate; 10246-75-0; Hydroxyzine-d4 dihydrochloride; 1244-76-4 (HCl); 5978-92-7 (pamoate ester)
|
Appearance |
Solid powder
|
SMILES |
C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
|
InChi Key |
ZQDWXGKKHFNSQK-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2
|
Chemical Name |
2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol
|
Synonyms |
NSC-169188; NSC169188; Hydroxyzine; NSC 169188; U.C.B 4492
|
HS Tariff Code |
2933.59.9500
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6673 mL | 13.3365 mL | 26.6731 mL | |
5 mM | 0.5335 mL | 2.6673 mL | 5.3346 mL | |
10 mM | 0.2667 mL | 1.3337 mL | 2.6673 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT06080100 | Not yet recruiting | Drug: Xenon Other: premedication hydroxyzine 25 mg |
Anesthesia Anxiety |
The S.N. Fyodorov Eye Microsurgery State Institution |
November 1, 2023 | Early Phase 1 |
NCT05680584 | Recruiting | Drug: Melatonin 3 MG Drug: Hydroxyzine Pill |
Effect of Drug Anxiety |
Minia University | February 1, 2023 | Phase 1 |
NCT05737511 | Not yet recruiting | Drug: Hydroxyzine Drug: Escitalopram Oxalate |
Panic Disorder | Sultan Qaboos University | December 30, 2023 | Phase 4 |
NCT04188106 | Completed | Drug: Varenicline Pill Drug: Hydroxyzine Pill |
Stress Nausea Smoking Cessation |
Rose Research Center, LLC | June 17, 2019 | Phase 4 |
NCT00661674 | Completed | Drug: Palonosetron Drug: Hydroxyzine |
Substance-Related Disorders | Stanford University | April 2008 | Not Applicable |
J Basic Clin Pharm . 2016 Sep;7(4):97-104. td> |